Approval · Notice of Compliance 24505 · 2020
ERAXIS: Notice of Compliance 24505
Issued October 28, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24505
- Date
- October 28, 2020
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the storage temperature and the in-use period for the eraxis infusion solution by removing the initially approved storage option of (stored frozen for at least 72 hours" including a cautionary statement "do not freeze"
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ERAXIS | Not yet assigned | — |
Medicinal ingredients
- ANIDULAFUNGIN 100 MG per VIAL